Reporting owner · CIK 0001968254

Krempa David

Visual SEC Form 4 history across 1 companies, 23 transactions and 4 filings.

CBOChief Business OfficerEton Pharmaceuticals, Inc.
Open-market mix
Latest filingAug 24, 2026, 09:19 PM
Filings4Form 4 records
Buying$00 purchases
Selling$4.9M6 sales
Net value−$4.9MBuys minus sells
Companies14 securities
Most recentAug 24, 2026exercise

Open-market buy performance

90-day forward return on this insider's open-market purchases

90d forward
Forward return is not available yet

We compute this from each buy's stock performance 90 days after the transaction. The price history is still being populated for this insider's their open-market buys, so the average and median will appear here once the daily price refresh has covered the relevant trading days.

Monthly open-market activity

Reported purchase and sale transaction counts

Buys Sells
530-3-5Jan 25Jan 265May 261Aug 26

Net value flow

Buys minus sells

Jan 25
$0
Jan 26
$0
May 26
−$3.2M
Aug 26
−$1.6M

Transaction texture

Ownership and ticket size

Average P/S size$809.4K
Median P/S size$857.2K
Direct23
Indirect0
Aug 24, 2026exercise

Filing-only signals

Deterministic matches in this insider's history

Cluster Sellingpattern1Derivative Transactionfiling-context10Direct Ownershipfiling-context23Large Holdings Increaseholdings6Large Holdings Reductionholdings7Large Salesize3Repeat Sellerpattern4

Latest Form 4 facts

Quick context from source filings

Latest transaction

sale at Eton Pharmaceuticals, Inc. on Aug 24, 2026 valued at $1,626,750.

Review SEC filing
Latest buy

No open-market insider purchase is available.

Latest sale

sale at Eton Pharmaceuticals, Inc. on Aug 24, 2026 valued at $1,626,750.

Review SEC filing

Associated companies

Visual map of known reporting history

ETONEton Pharmaceuticals, Inc.23 transactions · latest Aug 24, 2026, 09:19 PM
TickerInsiderRoleTypeSharesValueCodeSignals90d returnFiledTrans date
ETONKrempa David
CBO
exercise25.0k$0M
Derivative Transaction Direct Ownership Large Holdings Reduction
−2.2%08/2408/24
ETONKrempa David
CBO
sale25.0k-$162MS
Cluster Selling Direct Ownership Large Holdings Reduction+1
−2.2%08/2408/24
ETONKrempa David
CBO
exercise25.0k$18.2MM
Direct Ownership Large Holdings Increase
−2.2%08/2408/24
ETONKrempa David
CBO
exercise7.20k$0M
Derivative Transaction Direct Ownership
+94.5%05/2705/27
ETONKrempa David
CBO
exercise12.4k$0M
Derivative Transaction Direct Ownership
+94.5%05/2705/27
ETONKrempa David
CBO
exercise12.5k$0M
Derivative Transaction Direct Ownership Large Holdings Reduction
+94.5%05/2705/26
ETONKrempa David
CBO
exercise25.0k$0M
Derivative Transaction Direct Ownership
+94.5%05/2705/26
ETONKrempa David
CBO
exercise30.5k$0M
Derivative Transaction Direct Ownership
+94.5%05/2705/22
ETONKrempa David
CBO
sale19.6k-$61.9MS
Direct Ownership Large Holdings Reduction Repeat Seller
+94.5%05/2705/27
ETONKrempa David
CBO
exercise7.20k$2.57MM
Direct Ownership
+94.5%05/2705/27

Krempa David Insider Activity FAQ

SEC Form 4 context

Who is Krempa David?

Krempa David is a reporting owner in SEC Form 4 filings with reporting owner CIK 0001968254.

Which companies has Krempa David reported transactions for?

Eton Pharmaceuticals, Inc.

When was Krempa David's latest insider buy?

No open-market insider purchase is available for this period.

When was Krempa David's latest insider sale?

sale at Eton Pharmaceuticals, Inc. on Aug 24, 2026 valued at $1,626,750.

Where can I see the original SEC filings?

Each transaction row links directly to the source SEC filing so the reported Form 4 details can be reviewed.

Are performance metrics included?

This version does not calculate win rates, forward returns, benchmark-adjusted returns, or high-conviction scores.